QuantalX NeuroScience
Brain Health Made Accessible
Company Overview
Snapshot
Founded in March 2014 by Iftach Dolev and Hilla Fogel, QuantalX NeuroScience operates with 11–50 employees. The company has raised $8.6M across 4 funding rounds from 4 investors. In November 2025, QuantalX NeuroScience received FDA De Novo clearance for its Delphi-MD System, establishing a new modality for brain function assessment.
Business overview
QuantalX NeuroScience is a Health Tech & Life Sciences company focused on making brain health accessible through its core product, Delphi-MD. This FDA De Novo–authorized device utilizes Direct Electrophysiological Imaging technology to map brain activity, providing real-time functional responses. The company's technology offers clinicians a non-invasive tool for brain health insights across various care settings, serving markets within medical devices, diagnostics, and digital healthcare.
Strategic signal
In November 2025, QuantalX NeuroScience received FDA De Novo clearance for its Delphi-MD System, a first-of-its-kind functional neuro-imaging device. This clearance is a significant regulatory validation, establishing a new modality for brain function assessment and signaling strong market readiness and potential for widespread adoption in the medical diagnostics industry.
Company Intelligence Q&A
- What is the primary product developed by QuantalX NeuroScience?
- QuantalX NeuroScience developed Delphi-MD, an FDA De Novo–authorized device that uses Direct Electrophysiological Imaging technology to map brain activity and provide real-time functional responses for brain health assessment.
- When did QuantalX NeuroScience receive FDA De Novo clearance for its Delphi-MD System?
- In November 2025, QuantalX NeuroScience received FDA De Novo clearance for its Delphi-MD System, establishing a new modality of brain function assessment.
- Which investors participated in the December 2022 funding round?
- In December 2022, QuantalX NeuroScience received funding from Katao Venture Partners and Keiretsu Forum Northwest.
- What was a key strategic partnership for QuantalX NeuroScience in June 2024?
- In June 2024, QuantalX NeuroScience partnered with the University of Illinois Chicago to advance its US commercialization efforts.
- What regulatory milestone did QuantalX NeuroScience achieve in February 2025?
- In February 2025, QuantalX Neuroscience announced CE MDR approval for its Delphi-MD device, making brain health assessment available in the EU.